Name: Alectinib HCl
CAS#: 1256589-74-8 (HCl)
Chemical Formula: C30H35ClN4O2
Exact Mass:
Molecular Weight: 519.086
Elemental Analysis: C, 69.42; H, 6.80; Cl, 6.83; N, 10.79; O, 6.16
EOS Med Chem produce Alectinib,AF 802, CH 5424802, RO 5424802, Alecensa, 1256589-74-8 in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.
Alectinib,AF 802, CH 5424802, RO 5424802, Alecensa, 1256589-74-8 Intermediates, EOS Med Chem have 8; Alectinib,AF 802, CH 5424802, RO 5424802, Alecensa, 1256589-74-8 Impurity we have 10, all from GMP, FDA plant.
Now Alectinib,AF 802, CH 5424802, RO 5424802, Alecensa, 1256589-74-8 DMF document is preparing.
Until 2016, Aug, Alectinib,AF 802, CH 5424802, RO 5424802, Alecensa, 1256589-74-8 more than produced 25kg API, 120kg Intermediates
GMP PRODUCE:
Alectinib;Veliparib;Acalabrutinib;Venetoclax;Sotagliflozin;Ledipasvir;LX1606;Anacetrapib;Abemaciclib
Alectinib Alecensa;RG-7853; RO-5424802; AF-802; CH-5424802 1256580-46-7(free base)
Alectinib Alecensa;RG-7853; RO-5424802; AF-802; CH-5424802 1256589-74-8(HCl)
Alectinib Intermediates Ethyl 2-(4-bromophenyl)-2-methylpropanoate 32454-36-7
Alectinib Intermediates 2-(4-bromophenyl)-2-methylpropanoic acid 32454-35-6
Alectinib Intermediates 2-methyl-2-(4-vinylphenyl)propanoic acid 1256584-72-1
Alectinib Intermediates 2-(4-ethylphenyl)-2-methylpropanoic acid 1247119-83-0
Alectinib Intermediates 2-(4-ethyl-3-iodophenyl)-2-methylpropanoic acid 1256584-73-2
Alectinib Intermediates Tert-butyl 4-(4-ethyl-3-iodophenyl)-4-methyl-3-oxopentanoate 1256584-74-3
Alectinib Intermediates Tert-butyl 6-cyano-2-(2-(4-ethyl-3-iodophenyl)propan-2-yl)-1H-indole-3-carboxylate 1256585-29-1
Alectinib Intermediates 6-cyano-2-(2-(4-ethyl-3-(4-morpholinopiperidin-1-yl)phenyl)propan-2-yl)-1H-indole-3-carboxylic acid 1256584-78-7
Description: Alectinib, also known as AF802, or CH5424802 or RO5424802, is a potent, selective, and orally available ALK inhibitor with a unique chemical scaffold, showing preferential antitumor activity against cancers with gene alterations of ALK, such as nonsmall cell lung cancer (NSCLC) cells expressing EML4-ALK fusion and anaplastic large-cell lymphoma (ALCL) cells expressing NPM-ALK fusion in vitro and in vivo. Alectinib inhibited ALK L1196M, which corresponds to the gatekeeper mutation conferring common resistance to kinase inhibitors, and blocked EML4-ALK L1196M-driven cell growth. Alectinib (as HCl salt) was approved in Dec. 2015.
Synonym: AF 802; AF-802; AF802; CH5424802; CH5424802; CH 5424802; RO5424802; RO 5424802; RO5424802, Alectinib; brand name: Alecensa
IUPAC/Chemical Name: 9-ethyl-6,6-dimethyl-8-(4-morpholinopiperidin-1-yl)-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile hydrochloride
SMILES Code: N#CC1=CC2=C(C=C1)C3=C(C(C)(C)C4=CC(N5CCC(N6CCOCC6)CC5)=C(CC)C=C4C3=O)N2.[H]Cl
Related CAS#
CAS#1256580-46-7 (Alectinib free base)
CAS#1256589-74-8 (Alectinib HCl)
1: Ou SH, Weitz M, Jalas JR, Kelly DF, Wong V, Azada MC, Quines O, Klempner SJ. Alectinib induced CNS radiation necrosis in an ALK+NSCLC patient with a remote (7 years) history of brain radiation. Lung Cancer. 2016 Jun;96:15-8. doi: 10.1016/j.lungcan.2016.03.008. Epub 2016 Mar 26. PubMed PMID: 27133743.
2: Tchekmedyian N, Ali SM, Miller VA, Haura EB. Acquired ALK L1152R Mutation Confers Resistance to Ceritinib and Predicts Response to Alectinib. J Thorac Oncol. 2016 Apr 15. pii: S1556-0864(16)30081-8. doi: 10.1016/j.jtho.2016.03.018. [Epub ahead of print] PubMed PMID: 27091190.
3: Aikawa H, Hayashi M, Ryu S, Yamashita M, Ohtsuka N, Nishidate M, Fujiwara Y, Hamada A. Visualizing spatial distribution of alectinib in murine brain using quantitative mass spectrometry imaging. Sci Rep. 2016 Mar 30;6:23749. doi: 10.1038/srep23749. PubMed PMID: 27026287; PubMed Central PMCID: PMC4812395.
4: Dong X, Fernandez-Salas E, Li E, Wang S. Elucidation of Resistance Mechanisms to Second-Generation ALK Inhibitors Alectinib and Ceritinib in Non-Small Cell Lung Cancer Cells. Neoplasia. 2016 Mar;18(3):162-71. doi: 10.1016/j.neo.2016.02.001. PubMed PMID: 26992917; PubMed Central PMCID: PMC4796802.
5: Tanaka H, Taima K, Morimoto T, Nakamura K, Tanaka Y, Itoga M, Takanashi S, Okumura K. Dramatic response to alectinib in a patient of ALK-rearranged lung cancer with poor performance status. BMC Res Notes. 2016 Mar 17;9(1):173. doi: 10.1186/s13104-016-1983-9. PubMed PMID: 26987388; PubMed Central PMCID: PMC4794901.
6: Yoshida T, Hida T, Yatabe Y. Rapid and dramatic response to alectinib in an ALK rearranged non-small-cell lung cancer patient who are critically ill. Anticancer Drugs. 2016 Mar 2. [Epub ahead of print] PubMed PMID: 26938871.
7: Yoshimura Y, Kurasawa M, Yorozu K, Puig O, Bordogna W, Harada N. Antitumor activity of alectinib, a selective ALK inhibitor, in an ALK-positive NSCLC cell line harboring G1269A mutation : Efficacy of alectinib against ALK G1269A mutated cells. Cancer Chemother Pharmacol. 2016 Mar;77(3):623-8. doi: 10.1007/s00280-016-2977-y. Epub 2016 Feb 5. PubMed PMID: 26849637.
8: Gainor JF, Chi AS, Logan J, Hu R, Oh KS, Brastianos PK, Shih HA, Shaw AT. Alectinib Dose Escalation Reinduces Central Nervous System Responses in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer Relapsing on Standard Dose Alectinib. J Thorac Oncol. 2016 Feb;11(2):256-60. doi: 10.1016/j.jtho.2015.10.010. Epub 2015 Dec 18. PubMed PMID: 26845119; PubMed Central PMCID: PMC4743545.
9: Takegawa N, Hayashi H, Iizuka N, Takahama T, Ueda H, Tanaka K, Takeda M, Nakagawa K. Transformation of ALK rearrangement-positive adenocarcinoma to small-cell lung cancer in association with acquired resistance to alectinib. Ann Oncol. 2016 May;27(5):953-5. doi: 10.1093/annonc/mdw032. Epub 2016 Jan 24. PubMed PMID: 26811347.
10: Pirker R, Filipits M. Alectinib in RET-rearranged non-small cell lung cancer-Another progress in precision medicine? Transl Lung Cancer Res. 2015 Dec;4(6):797-800. doi: 10.3978/j.issn.2218-6751.2015.03.08. PubMed PMID: 26798590; PubMed Central PMCID: PMC4700226.
11: Fujita S, Masago K, Katakami N, Yatabe Y. Transformation to SCLC after Treatment with the ALK Inhibitor Alectinib. J Thorac Oncol. 2016 Jan 2. pii: S1556-0864(15)00275-0. doi: 10.1016/j.jtho.2015.12.105. [Epub ahead of print] PubMed PMID: 26751586.
12: Alectinib Approved for ALK+ Lung Cancer. Cancer Discov. 2016 Feb;6(2):115. doi: 10.1158/2159-8290.CD-NB2016-001. Epub 2016 Jan 6. PubMed PMID: 26739884.
13: Isozaki H, Ichihara E, Takigawa N, Ohashi K, Ochi N, Yasugi M, Ninomiya T, Yamane H, Hotta K, Sakai K, Matsumoto K, Hosokawa S, Bessho A, Sendo T, Tanimoto M, Kiura K. Non-Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases. Cancer Res. 2016 Mar 15;76(6):1506-16. doi: 10.1158/0008-5472.CAN-15-1010. Epub 2015 Dec 30. PubMed PMID: 26719536.
14: Shaw AT, Gandhi L, Gadgeel S, Riely GJ, Cetnar J, West H, Camidge DR, Socinski MA, Chiappori A, Mekhail T, Chao BH, Borghaei H, Gold KA, Zeaiter A, Bordogna W, Balas B, Puig O, Henschel V, Ou SH; study investigators. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncol. 2016 Feb;17(2):234-42. doi: 10.1016/S1470-2045(15)00488-X. Epub 2015 Dec 19. PubMed PMID: 26708155; PubMed Central PMCID: PMC4752892.
15: Jassem J. Alectinib in crizotinib-resistant, ALK-positive NSCLC. Lancet Oncol. 2016 Feb;17(2):134-5. doi: 10.1016/S1470-2045(15)00555-0. Epub 2015 Dec 19. PubMed PMID: 26708154.
16: Tani T, Yasuda H, Hamamoto J, Kuroda A, Arai D, Ishioka K, Ohgino K, Miyawaki M, Kawada I, Naoki K, Hayashi Y, Betsuyaku T, Soejima K. Activation of EGFR Bypass Signaling by TGFα Overexpression Induces Acquired Resistance to Alectinib in ALK-Translocated Lung Cancer Cells. Mol Cancer Ther. 2016 Jan;15(1):162-71. doi: 10.1158/1535-7163.MCT-15-0084. Epub 2015 Dec 18. PubMed PMID: 26682573.
17: Miyamoto S, Ikushima S, Ono R, Awano N, Kondo K, Furuhata Y, Fukumoto K, Kumasaka T. Transformation to small-cell lung cancer as a mechanism of acquired resistance to crizotinib and alectinib. Jpn J Clin Oncol. 2016 Feb;46(2):170-3. doi: 10.1093/jjco/hyv173. Epub 2015 Nov 27. PubMed PMID: 26613679.
18: Ou SH, Ahn JS, De Petris L, Govindan R, Yang JC, Hughes B, Lena H, Moro-Sibilot D, Bearz A, Ramirez SV, Mekhail T, Spira A, Bordogna W, Balas B, Morcos PN, Monnet A, Zeaiter A, Kim DW. Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study. J Clin Oncol. 2016 Mar 1;34(7):661-8. doi: 10.1200/JCO.2015.63.9443. Epub 2015 Nov 23. PubMed PMID: 26598747.
19: Song Z, Wang M, Zhang A. Alectinib: a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically-acquired resistance. Acta Pharm Sin B. 2015 Jan;5(1):34-7. doi: 10.1016/j.apsb.2014.12.007. Epub 2015 Jan 24. Review. PubMed PMID: 26579422; PubMed Central PMCID: PMC4629211.
20: Takeuchi K, Togashi Y, Kamihara Y, Fukuyama T, Yoshioka H, Inoue A, Katsuki H, Kiura K, Nakagawa K, Seto T, Maemondo M, Hida T, Harada M, Ohe Y, Nogami N, Yamamoto N, Nishio M, Tamura T. Prospective and clinical validation of ALK immunohistochemistry: results from the phase I/II study of alectinib for ALK-positive lung cancer (AF-001JP study). Ann Oncol. 2016 Jan;27(1):185-92. doi: 10.1093/annonc/mdv501. Epub 2015 Oct 20. PubMed PMID: 26487585; PubMed Central PMCID: PMC4684157.
CAS#: 1256589-74-8 (HCl)
Chemical Formula: C30H35ClN4O2
Exact Mass:
Molecular Weight: 519.086
Elemental Analysis: C, 69.42; H, 6.80; Cl, 6.83; N, 10.79; O, 6.16
EOS Med Chem produce Alectinib,AF 802, CH 5424802, RO 5424802, Alecensa, 1256589-74-8 in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.
Alectinib,AF 802, CH 5424802, RO 5424802, Alecensa, 1256589-74-8 Intermediates, EOS Med Chem have 8; Alectinib,AF 802, CH 5424802, RO 5424802, Alecensa, 1256589-74-8 Impurity we have 10, all from GMP, FDA plant.
Now Alectinib,AF 802, CH 5424802, RO 5424802, Alecensa, 1256589-74-8 DMF document is preparing.
Until 2016, Aug, Alectinib,AF 802, CH 5424802, RO 5424802, Alecensa, 1256589-74-8 more than produced 25kg API, 120kg Intermediates
GMP PRODUCE:
Alectinib;Veliparib;Acalabrutinib;Venetoclax;Sotagliflozin;Ledipasvir;LX1606;Anacetrapib;Abemaciclib
2016 Mumbai CPHI, Hope to meet!
2016 Barcelona CPHI, Hope to meet!
2016 Korea(한국) CPHI, C40, Welcome!
2016 Shanghai CPHI, W5C47, Welcome!
EOS Med Chem, Medchem is Big
執大象，天下往，往而無害，安平泰
辦公室: 0086-531-69905422-806(直通)
攜帶番號 & WhatsApp: +8618653174435
Skype: willgutian
Alectinib Alecensa;RG-7853; RO-5424802; AF-802; CH-5424802 1256580-46-7(free base)
Alectinib Alecensa;RG-7853; RO-5424802; AF-802; CH-5424802 1256589-74-8(HCl)
Alectinib Intermediates Ethyl 2-(4-bromophenyl)-2-methylpropanoate 32454-36-7
Alectinib Intermediates 2-(4-bromophenyl)-2-methylpropanoic acid 32454-35-6
Alectinib Intermediates 2-methyl-2-(4-vinylphenyl)propanoic acid 1256584-72-1
Alectinib Intermediates 2-(4-ethylphenyl)-2-methylpropanoic acid 1247119-83-0
Alectinib Intermediates 2-(4-ethyl-3-iodophenyl)-2-methylpropanoic acid 1256584-73-2
Alectinib Intermediates Tert-butyl 4-(4-ethyl-3-iodophenyl)-4-methyl-3-oxopentanoate 1256584-74-3
Alectinib Intermediates Tert-butyl 6-cyano-2-(2-(4-ethyl-3-iodophenyl)propan-2-yl)-1H-indole-3-carboxylate 1256585-29-1
Alectinib Intermediates 6-cyano-2-(2-(4-ethyl-3-(4-morpholinopiperidin-1-yl)phenyl)propan-2-yl)-1H-indole-3-carboxylic acid 1256584-78-7
Description: Alectinib, also known as AF802, or CH5424802 or RO5424802, is a potent, selective, and orally available ALK inhibitor with a unique chemical scaffold, showing preferential antitumor activity against cancers with gene alterations of ALK, such as nonsmall cell lung cancer (NSCLC) cells expressing EML4-ALK fusion and anaplastic large-cell lymphoma (ALCL) cells expressing NPM-ALK fusion in vitro and in vivo. Alectinib inhibited ALK L1196M, which corresponds to the gatekeeper mutation conferring common resistance to kinase inhibitors, and blocked EML4-ALK L1196M-driven cell growth. Alectinib (as HCl salt) was approved in Dec. 2015.
Synonym: AF 802; AF-802; AF802; CH5424802; CH5424802; CH 5424802; RO5424802; RO 5424802; RO5424802, Alectinib; brand name: Alecensa
IUPAC/Chemical Name: 9-ethyl-6,6-dimethyl-8-(4-morpholinopiperidin-1-yl)-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile hydrochloride
SMILES Code: N#CC1=CC2=C(C=C1)C3=C(C(C)(C)C4=CC(N5CCC(N6CCOCC6)CC5)=C(CC)C=C4C3=O)N2.[H]Cl
Related CAS#
CAS#1256580-46-7 (Alectinib free base)
CAS#1256589-74-8 (Alectinib HCl)
1: Ou SH, Weitz M, Jalas JR, Kelly DF, Wong V, Azada MC, Quines O, Klempner SJ. Alectinib induced CNS radiation necrosis in an ALK+NSCLC patient with a remote (7 years) history of brain radiation. Lung Cancer. 2016 Jun;96:15-8. doi: 10.1016/j.lungcan.2016.03.008. Epub 2016 Mar 26. PubMed PMID: 27133743.
2: Tchekmedyian N, Ali SM, Miller VA, Haura EB. Acquired ALK L1152R Mutation Confers Resistance to Ceritinib and Predicts Response to Alectinib. J Thorac Oncol. 2016 Apr 15. pii: S1556-0864(16)30081-8. doi: 10.1016/j.jtho.2016.03.018. [Epub ahead of print] PubMed PMID: 27091190.
3: Aikawa H, Hayashi M, Ryu S, Yamashita M, Ohtsuka N, Nishidate M, Fujiwara Y, Hamada A. Visualizing spatial distribution of alectinib in murine brain using quantitative mass spectrometry imaging. Sci Rep. 2016 Mar 30;6:23749. doi: 10.1038/srep23749. PubMed PMID: 27026287; PubMed Central PMCID: PMC4812395.
4: Dong X, Fernandez-Salas E, Li E, Wang S. Elucidation of Resistance Mechanisms to Second-Generation ALK Inhibitors Alectinib and Ceritinib in Non-Small Cell Lung Cancer Cells. Neoplasia. 2016 Mar;18(3):162-71. doi: 10.1016/j.neo.2016.02.001. PubMed PMID: 26992917; PubMed Central PMCID: PMC4796802.
5: Tanaka H, Taima K, Morimoto T, Nakamura K, Tanaka Y, Itoga M, Takanashi S, Okumura K. Dramatic response to alectinib in a patient of ALK-rearranged lung cancer with poor performance status. BMC Res Notes. 2016 Mar 17;9(1):173. doi: 10.1186/s13104-016-1983-9. PubMed PMID: 26987388; PubMed Central PMCID: PMC4794901.
6: Yoshida T, Hida T, Yatabe Y. Rapid and dramatic response to alectinib in an ALK rearranged non-small-cell lung cancer patient who are critically ill. Anticancer Drugs. 2016 Mar 2. [Epub ahead of print] PubMed PMID: 26938871.
7: Yoshimura Y, Kurasawa M, Yorozu K, Puig O, Bordogna W, Harada N. Antitumor activity of alectinib, a selective ALK inhibitor, in an ALK-positive NSCLC cell line harboring G1269A mutation : Efficacy of alectinib against ALK G1269A mutated cells. Cancer Chemother Pharmacol. 2016 Mar;77(3):623-8. doi: 10.1007/s00280-016-2977-y. Epub 2016 Feb 5. PubMed PMID: 26849637.
8: Gainor JF, Chi AS, Logan J, Hu R, Oh KS, Brastianos PK, Shih HA, Shaw AT. Alectinib Dose Escalation Reinduces Central Nervous System Responses in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer Relapsing on Standard Dose Alectinib. J Thorac Oncol. 2016 Feb;11(2):256-60. doi: 10.1016/j.jtho.2015.10.010. Epub 2015 Dec 18. PubMed PMID: 26845119; PubMed Central PMCID: PMC4743545.
9: Takegawa N, Hayashi H, Iizuka N, Takahama T, Ueda H, Tanaka K, Takeda M, Nakagawa K. Transformation of ALK rearrangement-positive adenocarcinoma to small-cell lung cancer in association with acquired resistance to alectinib. Ann Oncol. 2016 May;27(5):953-5. doi: 10.1093/annonc/mdw032. Epub 2016 Jan 24. PubMed PMID: 26811347.
10: Pirker R, Filipits M. Alectinib in RET-rearranged non-small cell lung cancer-Another progress in precision medicine? Transl Lung Cancer Res. 2015 Dec;4(6):797-800. doi: 10.3978/j.issn.2218-6751.2015.03.08. PubMed PMID: 26798590; PubMed Central PMCID: PMC4700226.
11: Fujita S, Masago K, Katakami N, Yatabe Y. Transformation to SCLC after Treatment with the ALK Inhibitor Alectinib. J Thorac Oncol. 2016 Jan 2. pii: S1556-0864(15)00275-0. doi: 10.1016/j.jtho.2015.12.105. [Epub ahead of print] PubMed PMID: 26751586.
12: Alectinib Approved for ALK+ Lung Cancer. Cancer Discov. 2016 Feb;6(2):115. doi: 10.1158/2159-8290.CD-NB2016-001. Epub 2016 Jan 6. PubMed PMID: 26739884.
13: Isozaki H, Ichihara E, Takigawa N, Ohashi K, Ochi N, Yasugi M, Ninomiya T, Yamane H, Hotta K, Sakai K, Matsumoto K, Hosokawa S, Bessho A, Sendo T, Tanimoto M, Kiura K. Non-Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases. Cancer Res. 2016 Mar 15;76(6):1506-16. doi: 10.1158/0008-5472.CAN-15-1010. Epub 2015 Dec 30. PubMed PMID: 26719536.
14: Shaw AT, Gandhi L, Gadgeel S, Riely GJ, Cetnar J, West H, Camidge DR, Socinski MA, Chiappori A, Mekhail T, Chao BH, Borghaei H, Gold KA, Zeaiter A, Bordogna W, Balas B, Puig O, Henschel V, Ou SH; study investigators. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncol. 2016 Feb;17(2):234-42. doi: 10.1016/S1470-2045(15)00488-X. Epub 2015 Dec 19. PubMed PMID: 26708155; PubMed Central PMCID: PMC4752892.
15: Jassem J. Alectinib in crizotinib-resistant, ALK-positive NSCLC. Lancet Oncol. 2016 Feb;17(2):134-5. doi: 10.1016/S1470-2045(15)00555-0. Epub 2015 Dec 19. PubMed PMID: 26708154.
16: Tani T, Yasuda H, Hamamoto J, Kuroda A, Arai D, Ishioka K, Ohgino K, Miyawaki M, Kawada I, Naoki K, Hayashi Y, Betsuyaku T, Soejima K. Activation of EGFR Bypass Signaling by TGFα Overexpression Induces Acquired Resistance to Alectinib in ALK-Translocated Lung Cancer Cells. Mol Cancer Ther. 2016 Jan;15(1):162-71. doi: 10.1158/1535-7163.MCT-15-0084. Epub 2015 Dec 18. PubMed PMID: 26682573.
17: Miyamoto S, Ikushima S, Ono R, Awano N, Kondo K, Furuhata Y, Fukumoto K, Kumasaka T. Transformation to small-cell lung cancer as a mechanism of acquired resistance to crizotinib and alectinib. Jpn J Clin Oncol. 2016 Feb;46(2):170-3. doi: 10.1093/jjco/hyv173. Epub 2015 Nov 27. PubMed PMID: 26613679.
18: Ou SH, Ahn JS, De Petris L, Govindan R, Yang JC, Hughes B, Lena H, Moro-Sibilot D, Bearz A, Ramirez SV, Mekhail T, Spira A, Bordogna W, Balas B, Morcos PN, Monnet A, Zeaiter A, Kim DW. Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study. J Clin Oncol. 2016 Mar 1;34(7):661-8. doi: 10.1200/JCO.2015.63.9443. Epub 2015 Nov 23. PubMed PMID: 26598747.
19: Song Z, Wang M, Zhang A. Alectinib: a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically-acquired resistance. Acta Pharm Sin B. 2015 Jan;5(1):34-7. doi: 10.1016/j.apsb.2014.12.007. Epub 2015 Jan 24. Review. PubMed PMID: 26579422; PubMed Central PMCID: PMC4629211.
20: Takeuchi K, Togashi Y, Kamihara Y, Fukuyama T, Yoshioka H, Inoue A, Katsuki H, Kiura K, Nakagawa K, Seto T, Maemondo M, Hida T, Harada M, Ohe Y, Nogami N, Yamamoto N, Nishio M, Tamura T. Prospective and clinical validation of ALK immunohistochemistry: results from the phase I/II study of alectinib for ALK-positive lung cancer (AF-001JP study). Ann Oncol. 2016 Jan;27(1):185-92. doi: 10.1093/annonc/mdv501. Epub 2015 Oct 20. PubMed PMID: 26487585; PubMed Central PMCID: PMC4684157.
